Imatinib

Gleevec

Kinase Inhibitor

NADAC/unit $0.8271

No Shortage Tier 1: 39.5% PA Req: 169.6% 12 Manufacturers 24 ANDAs

Imatinib targets specific kinase enzymes involved in cancer cell growth and proliferation.

vs. brand Gleevec: Generic saves up to 92% per unit

Covered Lives

Generic Manufacturers

APOTEX INCCHARTWELL RX SCIENCES LLCCSPC OUYI PHARMACEUTICAL CO LTDDR REDDYS LABORATORIES LTDEUGIA PHARMA SPECIALITIES LTDHETERO LABS LTD UNIT VMYLAN PHARMACEUTICALS INCNATCO PHARMA LTDNOVARTIS PHARMACEUTICALS CORPQILU PHARMACEUTICAL HAINAN CO LTDSHILPA MEDICARE LTDSHORLA ONCOLOGYTEVA PHARMACEUTICALS USAZYDUS PHARMACEUTICALS USA INC

Explore in the Ecosystem

rxsaver.aiCompare prices for Imatinib drfinder.aiFind doctors who prescribe Imatinib rxpbm.aiPBM spread analysis for Imatinib clinicalrx.aiClinical profile: Imatinib

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.